OncoMatch/Clinical Trials/NCT02870244
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Is NCT02870244 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Escalating Doses for melanoma.
Treatment: Escalating Doses — Phase I clinical trial to determine the Phase II dose of autologous TIL 1383I TCR gene modified T Cells using a retrovirus. This is a novel National Cancer Institute (NCI) funded investigator initiated therapy for patients with advanced melanoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Biomarker criteria
Required: HLA-A2 positive
Required: TYR positive
Allowed: BRAF v600e
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: immunotherapy targeting tyrosinase
Patients that have undergone immunotherapy targeting tyrosinase.
Cannot have received: immunotherapy in combination with non-myeloablative chemotherapy
Patients that have undergone immunotherapy in combination with non-myeloablative chemotherapy.
Cannot have received: chemotherapy
Exception: within 4 weeks of study start
Patients who have received any chemotherapy or investigational treatment within 4 weeks of study start.
Cannot have received: investigational treatment
Exception: within 4 weeks of study start
Patients who have received any chemotherapy or investigational treatment within 4 weeks of study start.
Lab requirements
Blood counts
Absolute neutrophil count less than 1.5 x 10^9/L; Platelet count less than 100 x 10^9/L; International Normalized Ratio, INR greater than 1.5
Kidney function
Serum creatinine calculated creatinine clearance by the method of Cockcroft and Gault, less than 50mL min.
Liver function
Serum bilirubin greater than 1.5 x upper limit of normal ULN; Serum ALT, AST greater than 2.5 x ULN; Serum ALP greater than 2 x ULN; Serum Albumin less than 2.5 g dL
Cardiac function
Cardiac ejection fraction greater than 50 percent as determined by screening echocardiogram
Any of the following abnormal laboratory values Absolute neutrophil count less than 1.5 x 10^9/L Platelet count less than 100 x 10^9/L Serum bilirubin greater than 1.5 x upper limit of normal ULN Serum ALT, AST greater than 2.5 x ULN Serum ALP greater than 2 x ULN Serum Albumin less than 2.5 g dL International Normalized Ratio, INR greater than 1.5 Serum creatinine calculated creatinine clearance by the method of Cockcroft and Gault, less than 50mL min. Cardiac ejection fraction greater than 50 percent as determined by screening echocardiogram.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Loyola University Medical Center · Maywood, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT02870244 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immunotherapy targeting tyrosinase, immunotherapy in combination with non-myeloablative chemotherapy, chemotherapy disqualifies patients from enrollment.
Does this trial require HLA-A2?
Yes, HLA-A2 positive is a required biomarker for enrollment.
Does this trial require TYR?
Yes, TYR positive is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 89 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages